Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 255Breast Neoplasms 172Neoplasms 167Colorectal Neoplasms 154Neoplasm Metastasis 127Melanoma 119Recurrence 116Prostatic Neoplasms 116Leukemia, Myeloid, Acute 115Pancreatic Neoplasms 113Ovarian Neoplasms 110Multiple Myeloma 103Lung Neoplasms 95Stomach Neoplasms 89Squamous Cell Carcinoma of Head and Neck 82Triple Negative Breast Neoplasms 81Glioblastoma 81Lymphoma 76Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 64Carcinoma, Renal Cell 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 57Small Cell Lung Carcinoma 54Sarcoma 52Uterine Cervical Neoplasms 51Myelodysplastic Syndromes 51Advanced Solid Tumors 49

Interventions

Doxycycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neurofibromatosis 2 × 1 year × Clear all
NCT07131722 2026-01-23

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

PRG Science & Technology Co., Ltd.

Phase 1/2 Not yet recruiting
25 enrolled
CNS

Neurofibromatosis 2

NCT05521048 2025-12-08

Doxycycline in Cutaneous Schwannoma (NF2)

Massachusetts Eye and Ear Infirmary

Phase 1/2 Active not recruiting
19 enrolled
CNS

Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡